Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) (PERMIN)

This study has been completed.
Information provided by (Responsible Party):
Pierre Fabre Medicament Identifier:
First received: May 22, 2012
Last updated: January 14, 2014
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)